Ameritas Investment Partners’s Adicet Bio ACET Stock Holding History

Ameritas Investment Partners’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-134	Closed	-$5.04K	–	3122
2024 Q1	$5.04K	Hold	134	–	–	﹤0.01%	2947
2023 Q4	$4.05K	Hold	134	–	–	﹤0.01%	3005
2023 Q3	$2.94K	Hold	134	–	–	﹤0.01%	3042
2023 Q2	$5.21K	Hold	134	–	–	﹤0.01%	3020
2023 Q1	$12.4K	Hold	134	–	–	﹤0.01%	2648
2022 Q4	$19K	Hold	134	–	–	﹤0.01%	2589
2022 Q3	$30K	Buy	134 +31	+30%	+$7.87K	﹤0.01%	2296
2022 Q2	$23K	Hold	103	–	–	﹤0.01%	2482
2022 Q1	$33K	Hold	103	–	–	﹤0.01%	2291
2021 Q4	$29K	Hold	103	–	–	﹤0.01%	2453
2021 Q3	$13K	Hold	103	–	–	﹤0.01%	2858
2021 Q2	$17K	Buy	+103	New	+$21K	﹤0.01%	2807
2020 Q2	–	Sell	-5	Closed	-$1K	–	3057
2020 Q1	$1K	Hold	5	–	–	﹤0.01%	2992
2019 Q4	$1K	Hold	5	–	–	﹤0.01%	2993
2019 Q3	$5K	Hold	5	–	–	﹤0.01%	2920
2019 Q2	$6K	Hold	5	–	–	﹤0.01%	2907
2019 Q1	$4K	Hold	5	–	–	﹤0.01%	2879
2018 Q4	$5K	Hold	5	–	–	﹤0.01%	2846
2018 Q3	$8K	Hold	5	–	–	﹤0.01%	2883
2018 Q2	$5K	Hold	5	–	–	﹤0.01%	2933
2018 Q1	$5K	Buy	+5	New	+$9.17K	﹤0.01%	2853

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Ameritas Investment Partners's ACET Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 134 shares — an estimated $5.04K sold.

Ameritas Investment Partners first reported a position in ACET in Q1 2018 and held it in 21 quarters. The position peaked at $33K in Q1 2022. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

Ameritas Investment Partners reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 134 Adicet Bio shares in Q2 2024, an estimated $5.04K.
Ameritas Investment Partners first reported a position in Adicet Bio in Q1 2018 and held it in 21 quarters.
Ameritas Investment Partners's Adicet Bio position peaked at $33K in Q1 2022.
86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.